PeptiDream Inc (4587)

Tokyo
Currency in JPY
1,951.5
-62.5(-3.10%)
Closed
4587 Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Earnings results expected in 6 days
Fair Value
Day's Range
1,938.52,001.0
52 wk Range
1,242.03,060.0
Key Statistics
Edit
Bid/Ask
1,950.50 / 1,952.00
Prev. Close
2,014
Open
1,994
Day's Range
1,938.5-2,001
52 wk Range
1,242-3,060
Volume
751.7K
Average Volume (3m)
878K
1-Year Change
52.09%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
4587 Scorecardpro icon
Company’s Health
pro lockUnlock
Fair Value
pro lockUnlock Price
Fair Pricepro lock
Upsidepro lock
Price Target
3,442.9
Upside
+76.42%
Members' Sentiments
Bearish
Bullish
ProTips
RSI suggests the stock is in oversold territory
Show more

PeptiDream Company Profile

PeptiDream Inc., a biopharmaceutical company, engages in the discovery and development of constrained peptides, small molecules, and peptide-drug conjugate therapeutics. The company develops its products based on its Peptide Discovery Platform System, a drug finding platform that enables the production of non-standard peptide libraries for the identification of potent and selective macrocyclic peptide candidates, which then can be developed into peptide-based, small molecule-based, peptide-drug conjugate, and multi-functional peptide conjugates -based therapeutics and diagnostics. Its development pipeline include PD-L1 indicated for oncology and currently under Ph1 clinical phase development stage; PD-L1 BMS-986229 indicated for oncology and currently under Ph1 clinical phase development stage; CD38 BHV-1100 + NK Cells indicated for multiple myeloma and currently under Ph1 clinical phase development stage; S2-protein PA-001 indicated for COVID-19 and currently under Ph1 clinical phase development stage; GhR AZP-3813 indicated for acromegaly/NET and currently under Ph1 clinical phase development stage; Glypican-3 indicated for liver cancer and currently under preclinical development stage; Myostatin indicated for DMD/muscle disorders and currently under preclinical development stage; TfR indicated for neuromuscular disorders and currently under preclinical development stage; c-Kit indicated for allergic condition and currently under preclinical development stage; c-Met currently under preclinical development stage; and HA-protein indicated for influenza and currently under preclinical development stage. It also involved in the research, development, manufacture, sale, export, and import of various radiopharmaceutical and radio diagnostic products. It has a collaboration with Novartis Pharma AG. PeptiDream Inc. was incorporated in 2006 and is based in Kawasaki, Japan.

Employees
735
Market
Japan

Compare 4587 to Peers and Sector

Metrics to compare
4587
Peers
Sector
Relationship
P/E Ratio
14.9x−7.0x−0.6x
PEG Ratio
0.29−0.300.00
Price/Book
4.4x3.5x2.6x
Price / LTM Sales
5.3x84.0x3.1x
Upside (Analyst Target)
63.9%10.2%48.8%
Fair Value Upside
Unlock15.2%7.5%Unlock

Analyst Ratings

6 Buy
1 Hold
0 Sell
Ratings:
7 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 3,442.9
(+76.42% Upside)

Earnings

Latest Release
Nov 13, 2024
EPS / Forecast
-2.35 / 3.08
Revenue / Forecast
5.47B / 5.58B
EPS Revisions
Last 90 days

People Also Watch

2,471.5
6361
-0.54%
5,836.0
8136
-2.18%
1,394.0
4680
-0.14%
869.0
8698
-0.91%

FAQ

What Is the PeptiDream (4587) Stock Price Today?

The PeptiDream stock price today is 1,951.50

What Stock Exchange Does PeptiDream Trade On?

PeptiDream is listed and trades on the Tokyo stock exchange.

What Is the Stock Symbol for PeptiDream?

The stock symbol for PeptiDream is "4587."

What Is the PeptiDream Market Cap?

As of today, PeptiDream market cap is 253.52B.

What is PeptiDream Earnings Per Share?

The PeptiDream EPS is 132.05.

What Is the Next PeptiDream Earnings Date?

PeptiDream will release its next earnings report on 13 Feb 2025.

From a Technical Analysis Perspective, Is 4587 a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.